Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
344.72
+7.12 (2.11%)
At close: Jun 22, 2026, 4:00 PM EDT
342.98
-1.74 (-0.50%)
After-hours: Jun 22, 2026, 7:57 PM EDT
Amgen Revenue
Amgen had revenue of $8.62B in the quarter ending March 31, 2026, with 5.76% growth. This brings the company's revenue in the last twelve months to $37.22B, up 9.07% year-over-year. In the year 2025, Amgen had annual revenue of $36.75B with 9.95% growth.
Revenue (ttm)
$37.22B
Revenue Growth
+9.07%
P/S Ratio
5.00
Revenue / Employee
$1,181,587
Employees
31,500
Market Cap
186.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.75B | 3.33B | 9.95% |
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
| Dec 31, 2018 | 23.75B | 898.00M | 3.93% |
| Dec 31, 2017 | 22.85B | -142.00M | -0.62% |
| Dec 31, 2016 | 22.99B | 1.33B | 6.14% |
| Dec 31, 2015 | 21.66B | 1.60B | 7.97% |
| Dec 31, 2014 | 20.06B | 1.39B | 7.43% |
| Dec 31, 2013 | 18.68B | 1.41B | 8.17% |
| Dec 31, 2012 | 17.27B | 1.68B | 10.80% |
| Dec 31, 2011 | 15.58B | 529.00M | 3.51% |
| Dec 31, 2010 | 15.05B | 411.00M | 2.81% |
| Dec 31, 2009 | 14.64B | -361.00M | -2.41% |
| Dec 31, 2008 | 15.00B | 232.00M | 1.57% |
| Dec 31, 2007 | 14.77B | 503.00M | 3.53% |
| Dec 31, 2006 | 14.27B | 1.84B | 14.79% |
| Dec 31, 2005 | 12.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
AMGN News
- 5 days ago - The Healthcare M&A Wave - Forbes
- 6 days ago - Amgen price target raised to $303 from $295 at Mizuho - TheFly
- 8 days ago - Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PRNewsWire
- 9 days ago - Drugmakers race to find a place in the next wave of obesity drugs - CNBC
- 11 days ago - Amgen taps research firm to reassess Tavneos data - Reuters
- 11 days ago - Healthcare ETFs: From Broad Exposure to Big Breakthroughs - ETF Trends
- 12 days ago - Amgen price target raised to $340 from $332 at Morgan Stanley - TheFly
- 13 days ago - Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying - Forbes